Pavel Drastich
YOU?
Author Swipe
View article: Serological Markers of Intestinal Barrier Function and Inflammation as Potential Predictors of Recurrent Primary Sclerosing Cholangitis
Serological Markers of Intestinal Barrier Function and Inflammation as Potential Predictors of Recurrent Primary Sclerosing Cholangitis Open
The impairment of intestinal barrier function is implicated in primary sclerosing cholangitis, but the clinical evidence is scarce. Therefore, we performed a cross-sectional study to evaluate serological markers of inflammation and intesti…
View article: Limited validity of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis
Limited validity of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis Open
BACKGROUND Ulcerative colitis (UC) with concomitant primary sclerosing cholangitis (PSC) represents a distinct disease entity (PSC-UC). Mayo endoscopic subscore (MES) is a standard tool for assessing disease activity in UC but its relevanc…
View article: Extending limits: the longest recorded duodenojejunal bypass implant
Extending limits: the longest recorded duodenojejunal bypass implant Open
A 59-year-old patient with type 2 diabetes, dyslipidemia, and hypertension underwent the placement of a duodenojejunal bypass (EndoBarrier; GI Dynamics, Boston, Massachusetts, USA). At the time of the endoscopy procedure, the patient weigh…
View article: Limited Validity of Mayo Endoscopic Subscore in Ulcerative Colitis with Concomitant Primary Sclerosing Cholangitis
Limited Validity of Mayo Endoscopic Subscore in Ulcerative Colitis with Concomitant Primary Sclerosing Cholangitis Open
Background and Aims Ulcerative colitis (UC) with concomitant primary sclerosing cholangitis (PSC) represents a distinct disease entity (PSC-UC). Mayo endoscopic subscore (MES) is a standard tool for assessing disease activity in UC but its…
View article: Novel upper gastrointestinal bleeding sensor capsule: a first human feasibility and safety trial
Novel upper gastrointestinal bleeding sensor capsule: a first human feasibility and safety trial Open
Background/Aims: Upper gastrointestinal bleeding (UGIB) is the most common GI condition requiring hospitalization, and can be diagnosed by direct visualization. The present study aimed to evaluate the safety and feasibility of using the Pi…
View article: P023 Serological markers of intestinal barrier function in patients with primary sclerosing cholangitis after liver transplantation
P023 Serological markers of intestinal barrier function in patients with primary sclerosing cholangitis after liver transplantation Open
Background Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease associated with inflammatory bowel disease. Liver transplantation (LT) is the only curative treatment for most patients with PSC. Recurrence of PSC (rPSC) is …
View article: Long-term Results of Duodeno-jejunal Bypass in the Treatment of Obesity and Type 2 Diabetes
Long-term Results of Duodeno-jejunal Bypass in the Treatment of Obesity and Type 2 Diabetes Open
Purpose Obesity and its related severe comorbidities are increasing rapidly. The duodenal-jejunal bypass is an endoscopically implanted device (mimicking the Roux-en-Y gastric bypass) developed to support weight reduction and improve type …
View article: Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD Open
Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term…
View article: A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review
A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review Open
Inflammatory bowel diseases (IBD) are systemic immune-mediated conditions with predilection for the gastrointestinal tract and include Crohn’s disease and ulcerative colitis. Despite the advances in the fields of basic and applied research…
View article: Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study Open
Background Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn’s disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune sy…
View article: Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures
Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures Open
Background: Second-generation thrombopoietin receptor agonists (TPO-RAs) are emerging as the new standard for managing thrombocytopenia (TCP) in patients with chronic liver diseases (CLDs) undergoing scheduled procedures. However, practica…
View article: Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy Open
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbi…
View article: Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial
Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial Open
Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease. Fecal microbial transplantation (FMT) is a promising alternative treatment. Methods: This multicenter, open-label, noninferiority trial randomized patients wit…
View article: Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study Open
Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of …
View article: Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy
Gut Microbiome Changes in Patients with Active Left-Sided Ulcerative Colitis after Fecal Microbiome Transplantation and Topical 5-aminosalicylic Acid Therapy Open
Ulcerative colitis (UC) is an inflammatory bowel disease, and intestinal bacteria are implicated in the pathogenesis of this disorder. The administration of aminosalicylates (5-ASA) is a conventional treatment that targets the mucosa, whil…
View article: Accuracy of Colon Capsule Endoscopy for Colorectal Neoplasia Detection in Individuals Referred for a Screening Colonoscopy
Accuracy of Colon Capsule Endoscopy for Colorectal Neoplasia Detection in Individuals Referred for a Screening Colonoscopy Open
Backround . Capsule colonoscopy might present an alternative to colonoscopy for colorectal neoplasia screening. Aim . To assess the accuracy of second-generation capsule colonoscopy (CCE2) for colorectal neoplasia detection compared with c…
View article: Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response
Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response Open
Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC-IBD), share three major pathogenetic mechanisms of inflammatory bowel disease (IBD)-gut dysbiosis, gut b…
View article: Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with <i>de novo</i> inflammatory bowel disease
Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with <i>de novo</i> inflammatory bowel disease Open
De novo colitis and acute cellular rejection are clinical conditions significantly predisposed towards recurrence of PSC after liver transplantation.
View article: P501 Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
P501 Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports Open
BackgroundTreatment of active ulcerative colitis (UC) after orthotopic liver transplantation (OLTx) for primary sclerosing cholangitis (PSC) remains to be challenging. Anti-tumour necrosis factor alfa agents (anti-TNF) and vedolizumab are …
View article: P259 The clinical course of ulcerative colitis after orthotopic liver transplantation in context of HLA-DR mismatch
P259 The clinical course of ulcerative colitis after orthotopic liver transplantation in context of HLA-DR mismatch Open
Background: Primary sclerosing cholangitis (PSC) is a chronic liver disorder of unknown etiology, characterized by inflammation, fibrosis and stenoses of both extra- and intrahepatic bile ducts. For those who develop end – stage liver dise…
View article: Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis
Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis Open
PSC is associated with specific gut microbes independently of concomitant IBD and several bacterial taxa clearly distinguish IBD phenotypes (PSC-IBD and UC).
View article: Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis Open
This prospective observational study provides evidence of the effectiveness of CT-P13 in IBD.